2021
DOI: 10.1002/cncr.33990
|View full text |Cite
|
Sign up to set email alerts
|

Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy

Abstract: Background Angiogenesis has an important role in thymic epithelial tumors (TETs). Regorafenib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet‐derived growth factor receptor β (PDGFR‐β), and fibroblast growth factor receptors (FGFRs). This study explored the activity of regorafenib as monotherapy in patients with advanced or recurrent B2‐B3 thymoma (T) and thymic carcinoma (TC) previously treated with platinum‐containing chemotherapy. Methods A Fleming single‐arm, single‐stage, phase 2 … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
15
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(16 citation statements)
references
References 57 publications
1
15
0
Order By: Relevance
“…A correlation between VEGF expression and invasive growth pattern in TET has been reported; however, it seems that angiogenesis depends less on the expression of bFGF 65 . Based on these findings, there have been several studies which have evaluated the efficacy of antiangiogenic agents against TETs, especially in cases of advanced and recurrent tumors with promising results 67–69 . Nevertheless, their administration is presently not the standard of care.…”
Section: Methods ‐ Search Strategymentioning
confidence: 99%
See 1 more Smart Citation
“…A correlation between VEGF expression and invasive growth pattern in TET has been reported; however, it seems that angiogenesis depends less on the expression of bFGF 65 . Based on these findings, there have been several studies which have evaluated the efficacy of antiangiogenic agents against TETs, especially in cases of advanced and recurrent tumors with promising results 67–69 . Nevertheless, their administration is presently not the standard of care.…”
Section: Methods ‐ Search Strategymentioning
confidence: 99%
“… 65 Based on these findings, there have been several studies which have evaluated the efficacy of antiangiogenic agents against TETs, especially in cases of advanced and recurrent tumors with promising results. 67 , 68 , 69 Nevertheless, their administration is presently not the standard of care.…”
Section: Methods ‐ Search Strategymentioning
confidence: 99%
“…PFS was 7.5 months in thymic carcinomas ( 44 ). Finally, a phase II trial with TKI regorafenib, in patients with TETs who progressed after at least one line of chemotherapy recently reported results with a disease control rate of 78.9% ( 45 ).…”
Section: Targeted Agents In Tetsmentioning
confidence: 99%
“…Similarly, lenvatinib, another VEGFR/multikinase inhibitor, showed promising effects on advanced or metastatic thymic carcinomas, with presumably higher efficacy than sunitinib [ 127 ]. The RESOUND trial tested successfully regorafenib—a VEGFR, PDGFR, and FGFR inhibitor—as a well-tolerated monotherapy for advanced or recurrent B2 or B3 thymomas and thymic carcinomas [ 128 ].…”
Section: Diagnostic and Therapeutic Approachesmentioning
confidence: 99%